Primary Malignant Tumors of the Heart

Valente, Marialuisa; Rizzo, Stefania; Leone, Ornella; Basso, Cristina

doi:10.1007/978-1-62703-143-1_6

Cited by 3 publications

(2 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, sarcomas have been reported to present at later stages of life and are difficult to diagnose. 4 In contrast, we show here that patients with cardiac sarcomas present at a younger age than those with extracardiac disease.…”

Section: Discussionmentioning

confidence: 48%

“…[1][2][3] Because most practitioners may see only a handful of such cases in their lifetime, the accumulated experience on this subject has been collated and summarized in multiple extensive literature reviews. 1,4 Nevertheless, the core knowledge of PMCTs has continued to come from single-center studies consisting of surgical case series and autopsy reports. 2,[4][5][6][7] Because of the relatively small numbers and significant referral bias of these reports, the incidence of PMCTs remains unclear, their histology incompletely defined, and treatment ineffectual, and prognosis is thought to be universally poor.…”

mentioning

confidence: 43%

See 1 more Smart Citation

Characteristics and Survival of Malignant Cardiac Tumors

et al. 2015

View full text Add to dashboard Cite

Background-The aim of this study was to investigate the incidence, histopathology, demographics, and survival associated with primary malignant cardiac tumors (PMCTs). Methods and Results-We queried the Surveillance, Epidemiology and End Results (SEER) 18 registry from the National Cancer Institute for all PMCTs diagnosed from 1973 to 2011. We describe PMCT histopathology and incidence, comparing characteristics and survival of these patients with those of patients with extracardiac malignancies of similar histopathology. From a total of 7 384 580 cases of cancer registered in SEER, we identified 551 PMCTs (0.008%). The incidence of PMCT diagnosis is 34 cases per 100 million persons and has increased over time (25.1 in 1973-1989, 30.2 in 1990-1999, and 46.6 in 2000-2011). Most patients are female (54.1%) and white (78.6%) with median age at diagnosis of 50 years. The most common PMCTs are sarcomas (n=357, 64.8%), followed by lymphomas (n=150, 27%) and mesotheliomas (n=44, 8%). Most patients are diagnosed with tissue sample (96.8%). Although use of chemotherapy is not documented in SEER, 19% of patients received radiation and 44% had surgery. After a median follow-up of 80 months, 413 patients had died. The 1-, 3-, and 5-year survival rates were 46%, 22%, and 17% and have improved over the eras, with 1-, 3-, and 5-year survival rates of 32%, 17%, and 14% for 1973 to 1989 and 50%, 24%, and 19% for 2000 to 2011 (P=0.009). Cardiac sarcomas and mesotheliomas are the most lethal PMCTs, with 1-, 3-, 5-year survival rates of 47%, 16%, and 11% and of 51%, 26%, and 23% compared with 59%, 41%, and 34% for lymphomas, respectively (log rank test P<0.001). Patients with cardiac lymphomas and sarcomas are younger and have worse survival than patients with extracardiac disease of similar histopathology (P<0.001). Conclusions-PMCTs are extremely rare and continue to be associated with poor prognosis. Over the past 5 decades, the incidence and survival of patients diagnosed with PMCT appear to have increased.

show abstract

Section: Discussionmentioning

confidence: 48%

mentioning

confidence: 43%

Characteristics and Survival of Malignant Cardiac Tumors

et al. 2015

View full text Add to dashboard Cite

show abstract

Diagnosis of Primary Cardiac Malignancies: Echocardiography

Pino

Lestuzzi

2017

Manual of Cardio-Oncology

View full text Add to dashboard Cite

Malignant Cardiac Tumors: Diagnosis and Treatment

et al. 2015

View full text Add to dashboard Cite

Primary malignant cardiac tumors are represented by sarcomas and non-Hodgkin lymphomas. They are rare, affect mostly patients in the fourth decade of life and have a severe prognosis. Both the diagnosis and the treatment require a multidisciplinary approach, and the cardiologist plays a central role both in the diagnosis and in the follow-up. The prognosis may be improved by a careful planning of surgery and by the use of multimodality treatment, including complementary chemotherapy and radiation therapy. A strict follow-up must be planned even after apparently complete cure.

show abstract

Primary Malignant Tumors of the Heart

Cited by 3 publications

References 61 publications

Characteristics and Survival of Malignant Cardiac Tumors

Characteristics and Survival of Malignant Cardiac Tumors

Diagnosis of Primary Cardiac Malignancies: Echocardiography

Malignant Cardiac Tumors: Diagnosis and Treatment

Contact Info

Product

Resources

About